C Difficile Infection

The first half of 2025 recap for gastroenterology spotlights GI FDA approvals, clinical trial data, and new guidance on bowel preparation for colonoscopy.

The Q2 recap for gastroenterology spotlights top coverage from DDW, expert perspective on the importance of multidisciplinary care, and other new research.

The month in review spotlights perspectives on collaborative GI care, updates in C diff, and new research about disorders of gut brain interaction.

Phase 3 trial results show FMT was noninferior to standard-of-care vancomycin for patients with a first episode of C diff infection.

Use of an AI-guided infection prevention bundle did not significantly reduce CDI incidence but was associated with increased antimicrobial stewardship.

Test your knowledge of the AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases with this clinical quiz!

Investigators from the guideline panel discuss the AGA’s recommendations regarding the use of fecal microbiota-based therapies for CDI, IBD, and IBS.

The guideline recommends fecal microbiota transplant in most cases of recurrent Clostridioides difficile infection but does not suggest fecal microbiota-based therapies for IBD or IBS.

Participants given omadacycline had high fecal concentrations with a distinct microbiome profile compared to those in the vancomycin group, with study results calling attention to the importance of antibiotics’ impact on the gut microbiome.

Adding navy beans to one’s usual diet may be a viable dietary strategy for modulating the gut microbiome and regulating host markers associated with metabolic obesity and colorectal cancer.

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine.

Ciprofloxacin, ceftriaxone, and piperacillin/tazobactam showed the greatest associations with adverse drug reaction case reports related to CDI.

Although respondents agreed on the relevance of the gut microbiota in IBD, attitudes toward the clinical application of microbiome-based therapies varied.

A retrospective cohort study of inpatient encounters from 3 hospitals in the Duke University Health System showed greater rates of testing among White patients compared to Black and NWNB patients.

New phase 1b data supports further investigation into Adiso Therapeutic's prospective treatment.

New data presented at ACG 2023 showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.

Results showed autologous FMT was safe and well-tolerated but did not affect time to normalized intestinal habits compared to placebo.

Announced by AbbVie on October 15, 2023, positive results revealed 59% of patients treated with risankizumab and 40% of patients treated with ustekinumab achieved clinical remission, respectively.

Use of mirtazapine, nortriptyline, and trazodone among hospitalized patients was associated with a greater risk of CDI.

The approval of oral, once-daily etrasimod 2 mg was based on positive data from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials.

Age, fecal calprotectin level, toxin B PCR cycle threshold, immunosuppression, sex, and creatinine levels were identified as independent risk factors for developing recurrent CDI.

Social vulnerability index, race, and poverty were associated with increased rates of CDI, calling attention to population-level health disparities.

Results from the systematic review and meta-analysis showed FMT restored the normal microbiome, reduced the risk of gastrointestinal infections, and did not lead to increased adverse events in patients with HIV.

Findings revealed more than 5,000 excess deaths from CDI and 35.6% excess risk compared to the expected number of disease deaths calculated using data from the National Vital Statistics System.

Findings showed colonization with toxigenic C. difficile was associated with a greater risk of CDI during hospitalization than cross-transmission.